Management of post-chemotherapy residual masses in advanced seminoma

被引:62
|
作者
Fléchon, A [1 ]
Bompas, E [1 ]
Biron, P [1 ]
Droz, JP [1 ]
机构
[1] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
来源
JOURNAL OF UROLOGY | 2002年 / 168卷 / 05期
关键词
testes; seminoma; drug therapy; cisplatin; neoplasm; residual;
D O I
10.1016/S0022-5347(05)64275-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases. Materials and Methods: We retrospectively analyzed (1986 to 2000) residual mass evolution according to size in 79 platinum treated patients. Results: There was an evaluable response in 78 patients, including toxic death in 1 after 1 chemotherapy cycle, a complete response in 34 (after chemotherapy in 15 and after complete residual mass resection in 19), a marker negative partial response in 42 (incomplete residual mass resection in 8), stable and progressive disease in 1 each. In 15 of 31 patients the resected residual mass was 3 cm. or greater, whereas in 12 of 29 it was less than 3 cm. No surgery was performed for 3 residual masses of unknown size. Of the 42 residual masses 21 disappeared at a median of 12.5 months. Progression occurred at the initial tumor site in 11 of 13 patients after a median of 3.5 months, including 3 with a complete response, 8 with a marker negative partial response (residual mass 3 cm. or greater in 3, less than 3 cm. in 4 and unknown size in 1) and treatment failure in 2 (residual mass 3 cm. or greater). At a median followup of 36.4 months 67 patients survived (no disease progression in 56 and nonevolving residual masses in 11), while 12 had died including 9 of progressive disease 1 of toxicity and 2 of other causes. Conclusions: In our study there was incomplete surgical resection in 30% of cases. Relapse in 16.6% of cases occurred rapidly after the end of chemotherapy. Viable cells were only noted in residual masses 3 cm. or greater (13%) and 50% of residual masses disappeared during surveillance. We intend. to perform a prospective cohort study with close followup of patients with residual masses less than 3 cm. using an indication for surgery tailored to positron emission tomography findings in those with residual masses 3 cm. or greater.
引用
收藏
页码:1975 / 1979
页数:5
相关论文
共 50 条
  • [41] Diagnostic accuracy of F18-FDG PET in the post-chemotherapy management of patients with seminoma: a meta-analysis
    Treglia, G.
    Sadeghi, R.
    Annunziata, S.
    Caldarella, C.
    Bertagna, F.
    Giovanella, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S502 - S502
  • [42] Positron emission tomography scans in the evaluation of post-chemotherapy residual masses in patients with metastatic testicular tumors: A prospective study
    Thyavihally, Yuvaraja B.
    Sengar, Manju
    Rangarajan, Venkatesh
    Tongaonkar, Hemant B.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 269 - 269
  • [43] FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals
    Becherer, A
    De Santis, M
    Karanikas, G
    Szabó, M
    Bokemeyer, C
    Dohmen, BM
    Pont, J
    Dudczak, R
    Dittrich, C
    Kletter, K
    EUROPEAN JOURNAL OF RADIOLOGY, 2005, 54 (02) : 284 - 288
  • [44] 18FDG-PET/CT clinical impact in patients with pure testicular seminoma and residual retroperitoneal mass post-chemotherapy treatment
    Arceluz, M.
    Gonzalez, C.
    Traverso, S.
    Tinetti, C.
    Osorio, A.
    Bruno, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S480 - S480
  • [45] Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses
    Nakamura, Terukazu
    Oishi, Masakatsu
    Ueda, Takashi
    Fujihara, Atsuko
    Nakanishi, Hiroyuki
    Kamoi, Kazumi
    Naya, Yoshio
    Hongo, Fumiya
    Okihara, Koji
    Miki, Tsuneharu
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (07) : 663 - 668
  • [46] RESIDUAL MASS AFTER CHEMOTHERAPY FOR SEMINOMA - CHANGING CONCEPTS OF MANAGEMENT
    HERR, HW
    BOSL, G
    JOURNAL OF UROLOGY, 1987, 137 (06): : 1234 - 1235
  • [47] Post-chemotherapy residual tumor resection in patients with elevated tumor markers
    Che, Y.
    Winter, C.
    Siemer, Grosse R.
    Hiester, A.
    Albers, P.
    EUROPEAN UROLOGY, 2021, 79 : S910 - S910
  • [48] Surgical controversies in the management of post-chemotherapy nonretroperitoneal residual disease in metastatic nonseminomatous germ cell tumors
    Pandey, Durgatosh
    Garg, Pankaj Kumar
    Ray, Mukur Dipi
    Mishra, Ashutosh
    SOUTH ASIAN JOURNAL OF CANCER, 2016, 5 (01) : 20 - +
  • [49] Telomerase activity in testicular germ cell tumours and post-chemotherapy masses.
    Smith, GL
    Newlands, ES
    Christmas, TJ
    Harnden, P
    Burger, AM
    JOURNAL OF UROLOGY, 1998, 159 (05): : 164 - 164
  • [50] POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) FOR SEMINOMA: IS SURGERY EFFECTIVE?
    Tachibana, Isamu
    Alabd, Andre
    Whaley, Rumeal
    Mcfadden, Jacob
    Piroozi, Alex
    Kern, Sean
    Adra, Nabil
    Foster, Richard
    Einhorn, Lawrence
    Cary, Clint
    Masterson, Timothy
    JOURNAL OF UROLOGY, 2023, 209 : E687 - E688